Meet Alert — Personal Safety Built Into Every Pebblebee Clip for Instant Protection Just in Time for Back to School
'For over a decade, we've focused on helping people track what matters most,' said Pebblebee CEO and founder Daniel Daoura. 'But as a dad, I wanted more than just peace of mind over where something is — I wanted personal safety that's always within reach. So we built Alert. Now the same Clip that helps you find your keys can help keep you, or your loved ones, safe in a moment of crisis.'
New Rapid Press & Safety Circle Features
While most safety devices are bulky, obvious, or targeted to specific groups, Alert is inclusive by design — sleek, subtle, and already in your everyday carry. Whether you're a student walking home, a commuter on a late train, or a parent traveling with kids, Alert provides a quiet confidence: protection without stigma.
Here's how it works:
Rapid-press the Clip to trigger the siren and flashing strobe — even if your phone is out of reach.
Alert your Safety Circle (pre-selected contacts) via the Pebblebee app and backend services. Notifications are sent as long as your phone is nearby.
No subscription. No extra hardware. Just peace of mind built into what you already carry.
'Alert does for personal safety what smartphones did for cameras,' continued Daoura. 'It makes safety seamless — not something extra to remember, but something that's always with you.'
Pricing & Availability
Pebblebee Clip Universal is available now for $34.99 at Pebblebee.com, Amazon, and select retailers. Alert is included for free for new and existing customers.
Current Pebblebee customers can enable Alert through a free update in the Pebblebee app starting today.
About Pebblebee
Pebblebee is a tracking and personal safety company on a mission to make peace of mind effortless. For over 10 years, we've led innovation in smart, sustainable Bluetooth technology — evolving from simple item finders into a full-featured safety platform. Today, we blend sleek, rechargeable hardware with powerful software services that help people stay connected to what matters most — whether that's your keys, your bag, or your loved ones. Compatible with both Apple® Find My™ and Google's Find Hub™, Pebblebee products are built for real life: intuitive, sustainable, and rooted in empathy. Backed by thousands of reviews and a near five star rating, the new features like Safety Circle and Alert showcase how Pebblebee continues to redefine everyday protection. Learn more at pebblebee.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
15 minutes ago
- Business Wire
Ops Powerhouse Claire Alexander Launches Precision-Built Platform for Streamlined Operations, Scale and Growth
SEATTLE--(BUSINESS WIRE)--A new era of business building begins with the official launch of The Arch's Anvil, an operations and growth platform created by financial services industry veteran Claire Alexander (Alexander). Alexander aims to help service-based firms transform big visions into high-functioning businesses. Developed through years of in-the-trenches experience in financial services, insurance, and real estate, The Arch's Anvil brings a streamlined, centralized, and personalized approach to structuring and strengthening client-service operations, making it a powerful new tool for financial advisors, entrepreneurs, attorneys, CPAs, and other small business owners serving individual clients in service-based professions. We provide tools and structure, built collaboratively in just 10 weeks to help business owners bring their vision to life, allowing them to spend less time on administrative friction and more time focusing on what matters to their clients and their growth. Share Alexander's grounding principle for The Arch's Anvil is this: Intentional business owners – and even accidental entrepreneurs – are the architects of their future. The platform positions itself as the essential tool, or 'anvil,' to shape that vision into sustainable success. Having spent over a decade building systems, processes, and teams within the financial services industry, Alexander gained significant expertise. This included scaling internal operations at a wealth advisory firm to $3.5 billion in assets through various transitions like mergers, acquisitions, affiliations, and succession, which ultimately highlighted for her the pervasive operational gaps facing not only financial advisory firms but also service providers in adjacent professions. Many of the available resources were either disconnected, overly technical, or not tailored to the boutique service businesses that prioritize trust and tangible client outcomes. 'At The Arch's Anvil, we don't just advise; we're in the trenches with you, transforming your company vision into a powerful, client-facing service system,' noted Founder Claire Alexander. 'We deliver everything from custom email sequences and branded templates to the robust back-end tech stack, ensuring a seamless, hands-off experience for your team. We tackle the operational 'craziness'—from onboarding and training to workflow design—freeing up critical time and eliminating bottlenecks.' 'Our ultimate goal is to provide the tools and structure, built collaboratively in just 10 weeks, so you can bring your vision to life, faster, and without the piecemeal struggle,' Alexander added. 'This helps business owners spend less time on administrative friction and more time focusing on what matters to their clients and their growth. The additional time we'll spend together 1:1 is also a key part of the value proposition – and seeing the immediate interest and demand for this work has been energizing. I look forward to partnering with more right-fit clients to create meaningful results and invite them to connect with me through my website.' ELIMINATING OPERATIONAL FRICTION FOR BUSINESS OWNERS The platform's core function is to help professionals, such as financial advisors, CPAs, attorneys, real estate agents, insurance professionals, and trusted consultants, create a more manageable and efficient workflow. It's particularly tailored for firms that work with individual clients and require robust, repeatable processes to reliably deliver high-quality service. The Arch's Anvil addresses key pain points for service-based firms by centralizing communications, integrating business tools, standardizing workflows, improving transparency and accountability, easing onboarding, minimizing administrative burdens, and enabling firms to maintain organized and accessible records — all designed for efficient, client-focused operations. The platform is both tailored and flexible: The basic structure centers around a secure, centralized digital dashboard that serves as the operational hub for service-based businesses. When users log in, they are presented with a straightforward interface that organizes all their business resources, project deliverables, documents, and workflow materials, making this essential information easily accessible and all in one place. The design is intended to eliminate fragmented processes, eradicating the need to search through emails or use disconnected platforms to find important information. 'Claire took me through The Arch's Anvil platform, and I was truly impressed. Any business owner, especially those struggling with small business complexities like mine, would benefit from this solution,' said Marie Swift, Founder of Impact Communications and Host of Swift Chats in the Financial Services Industry, a video interview and podcast series. 'Claire's expertise in financial services, as well as her experience in real estate and insurance, shines through in how versatile and practical the platform is. It's clear that The Arch's Anvil can make operations much more streamlined and manageable for advisors, service firms, and anyone who needs an organized approach to serving clients.' View or listen to the Swift Chat interview with Claire Alexander here: 'I've had the privilege of working directly with Claire, and she is one of the most gifted operations professionals I've encountered. Claire brings structure, clarity, and momentum to every business she touches. Her ability to transform complexity into streamlined systems is exceptional,' said Scott Danner, Entrepreneur, M&A Strategist, Author, and Host of The High Performance Life Podcast. 'I fully support the launch of The Arch's Anvil and look forward to seeing the impact she will continue to make for service-based businesses across the country.' ABOUT CLAIRE ALEXANDER Claire Alexander is a seasoned operations leader with nearly a decade as a licensed financial advisor and insurance professional, distinguished by her hands-on experience in the operational trenches of thriving advisory firms. She was instrumental in scaling a financial advisory practice by building robust internal systems that contributed to $3 billion in assets under management growth in just four years. Alexander's expertise is comprehensive; she has led or managed every key department within a company, from marketing strategy and HR systems to meticulous bookkeeping, seamless client onboarding, rigorous compliance, and effective employee training. Her operational leadership extends beyond financial services to include managing multi-million-dollar construction projects, crafting systems for real estate and property management companies, and overseeing the complex operations of over 100 contractors and employees. Having personally built and scaled operational structures for multiple businesses, Alexander champions the conviction that true, lasting efficiency forms the bedrock of unstoppable growth. Through The Arch's Anvil, she brings this broad and practical expertise to service-based professionals seeking to transform their vision into a reliable, scalable business reality. ABOUT THE ARCH'S ANVIL The Arch's Anvil is a business operations platform built for service-based professionals such as financial advisors, CPAs, attorneys, real estate agents, insurance professionals, and trusted consultants — as well as other growth-minded business owners seeking to streamline client service workflows, strengthen internal operations, and achieve scalable growth. At its core is a centralized digital dashboard, allowing users to log in and access all operational resources, project deliverables, and essential documents in one secure location, replacing fragmented communications and disjointed systems with organized, accessible structure. The platform is shaped by direct industry experience and offers personalized setup and guidance to fit the unique needs of different client-focused businesses, ensuring workflows are both consistent and adaptable. The Arch's Anvil addresses challenges such as maintaining organized records, integrating tools, standardizing processes, and onboarding efficiently, ultimately enabling firms to reduce administrative friction and concentrate on delivering high-quality service. What truly sets The Arch's Anvil apart is the direct, hands-on support clients receive. Clients have direct access to its founder and benefit from weekly 1:1 strategy calls. During these calls, The Arch's Anvil breaks down the specific details of a company and focuses on the week's projects, ensuring their vision comes to life with dedicated guidance.
Business Wire
15 minutes ago
- Business Wire
DCL Logistics Launches SelectShip, an AI-Powered Shipping Engine Built for Peak Season Performance and Beyond
SAN FRANCISCO--(BUSINESS WIRE)-- DCL Logistics, a leading fulfillment partner for modern ecommerce brands, today announced the launch of SelectShip, an AI-powered shipping engine already being used by brands like Canopy, Cure Hydration, and NuFace to automate parcel decisions, reduce unforeseen delivery costs, and use real-time shipping market data to meet rising customer expectations without adding operational overhead. Brands are locking in logistics strategies for Q4, a season where fulfillment execution can make or break revenue. This year, a perfect storm of tariff uncertainty, rising supply chain costs, and heightened consumer expectations has put parcel operations under pressure. Most ecommerce teams are using static, outdated logic to manage a dynamic industry of fragmented carrier networks, volatile fees, and thinner margins than ever before—without the infrastructure to adapt in real time. DCL Logistics built SelectShip in response to the rising complexity of parcel delivery and the growing pressure on fulfillment teams to do more with less. The fully managed, AI-powered system automates thousands of shipping decisions in real time, optimizing for speed, cost, and reliability for each order. Embedded within DCL's fulfillment platform, SelectShip requires no new tools, dashboards, or configuration from the customer. 'Parcel delivery has become one of the most visible and unforgiving parts of the ecommerce experience,' said Dave Tu, President of DCL Logistics. 'SelectShip reflects our belief that fulfillment partners shouldn't just provide software. They should own the systems and execution that brands can rely on. This is not another tool. It's an intelligent system, fully operated by our team, that turns shipping from a liability into a competitive edge.' Already in Market, Already Delivering SelectShip is already live with leading ecommerce brands and delivering measurable improvements across cost, speed, and customer experience. Built to operate behind the scenes, the platform enables fast, intelligent shipping decisions without adding operational overhead. Operational Results to Date: Shipping costs have decreased by 12 to 19% on average Transit times from two key facilities improved from 3.1 to 2.3 days using standard shipping One-third of orders are now arriving next day Delivery area surcharges have been avoided in over 95% of cases 55 to 60% of shipments include photo proof of delivery for added transparency 'DCL is taking a forward-thinking approach by embedding real-time shipping intelligence directly into their fulfillment operations,' said Jason Murray, CEO and Co-Founder at Shipium. 'SelectShip reflects what modern logistics infrastructure should look like. Brands get adaptive, AI-powered performance without the overhead of managing rules, carriers, or disconnected tools.' Built to Operate, Not Just Inform Most 3PLs rely on outdated systems with static logic that only take into account a few of many thousands of critical shipping variables. DCL takes a different approach. SelectShip is a dynamic tool that leverages machine learning to evaluate thousands of critical variables in real time, ensuring every package is automatically optimized for speed, reliability and cost. It's fully managed and embedded within DCL's fulfillment stack, with routing intelligence powered by Shipium and execution handled entirely by DCL's transportation team. Core Features Include: AI-optimized routing based on real-time data across billions of network data points Automated carrier and service selection for every order at the time of manifest Built-in compliance and label validation safeguards Calculates for the all-in cost, not just the base rate – including all extra fees like fuel, surcharges and more Transparent invoicing that eliminates surprise fees Fast onboarding, with most brands live in under three weeks Seamless integration with DCL's eFactory platform, no extra tools required SelectShip builds on DCL's commitment to owning fulfillment end-to-end. It delivers intelligent, embedded infrastructure that adapts to each order in real time, without requiring customer-side complexity. This launch marks a broader shift in how DCL supports growth-stage brands: by turning shipping into a system, not a set of decisions. To learn more about SelectShip and how it integrates with DCL's fulfillment services, visit: About DCL Logistics DCL Logistics is a modern third-party logistics (3PL) provider that combines operational expertise with a technology-forward approach. For over 40 years, DCL has helped high-growth brands scale by delivering fast, flexible fulfillment solutions backed by high-touch customer service. Learn more at About Shipium Shipium is an end-to-end shipping platform that helps modern operators improve speed and reliability while reducing cost. Built by the team behind Amazon's shipping stack, Shipium brings enterprise-grade delivery performance through an API-first platform. Learn more at
Business Wire
15 minutes ago
- Business Wire
Newron Begins Enrollment in Pivotal Phase III
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. ('Newron') (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that following the completion of a 42 day-screening period and the review of the patients by the Independent Eligibility Committee, it has successfully randomized the first patients in its pivotal ENIGMA-TRS 1 Phase III development program. ENIGMA-TRS 1 will evaluate evenamide as an add-on therapy to current antipsychotics, including clozapine, in patients with treatment-resistant schizophrenia (TRS). Today's announcement marks an important milestone for the clinical advancement of evenamide for treatment-resistant schizophrenia patients who urgently need more effective therapeutic options. Share 'Today's announcement marks an important milestone for the clinical advancement of evenamide for treatment-resistant schizophrenia patients who urgently need more effective therapeutic options,' said Ravi Anand, CMO, Newron Pharmaceuticals. 'We look forward to advancing evenamide through this pivotal Phase III study and delivering an important benefit to patients in need.' ENIGMA-TRS 1 is an international, 52-week, randomized, double-blind, placebo-controlled Phase III study evaluating the efficacy, tolerability, and safety of the 15mg BID and 30mg BID therapeutic doses of evenamide compared to placebo. Patients on second-generation antipsychotics (SGAs), including clozapine, need to meet Treatment Response and Resistance Psychosis (TRRIP) international consensus criteria for TRS. ENIGMA-TRS 1 will enroll at least 600 patients at study centers in Europe, Asia, Latin America and Canada. Prior to randomization, patients undergo a 42-day screening period, during which their TRS diagnosis, antipsychotic plasma levels (background medication), and conformance to protocol selection criteria will be evaluated by an Independent Eligibility Assessment Committee (IEAC) of three leading international schizophrenia experts. The primary assessment of efficacy and safety will be performed 12 weeks after randomization to treatment. The study will continue double-blind and placebo-controlled until the 52-week time point. The 12-week results from the study are expected in Q4 2026. Results from previous Phase II (study 014/015) and Phase III (study 008A) studies have demonstrated evenamide's significant and increasing efficacy as an add-on therapy on multiple measures of psychopathology in patients with TRS and inadequate responders, respectively. These results also confirmed a favorable safety and tolerability profile, adding to the growing evidence that evenamide's glutamatergic inhibition mechanism of action offers an innovative therapeutic option to schizophrenia patients who are not benefiting from current antipsychotic treatments. ENIGMA-TRS 2, the second study of Newron's pivotal Phase III ENIGMA-TRS program, has been approved by the US Food and Drug Administration (FDA), and will be performed at centers in the US and selected additional countries. It will include at least 400 patients in a 12-week, randomized, double-blind, placebo-controlled Phase III study, designed to evaluate the efficacy, tolerability, and safety of the 15mg BID dose of evenamide. Patients will meet selection criteria and be reviewed by the above-mentioned IEAC. The analysis for determination of efficacy and safety will be performed after patients complete 12 weeks of participation in the trial. US investigational centers are expected to initiate the study by October 2025. About schizophrenia Approximately 25 million people worldwide are affected by schizophrenia. Despite more than 60 different types of atypical and typical antipsychotics used to treat schizophrenia globally, a considerable number of patients remain severely ill or resistant to treatment. Overall, 30-50% of patients do not respond to the available medications and are defined as treatment resistant. In addition to the patients with treatment-resistant schizophrenia (TRS), another 20-30% are described as 'poor responders to antipsychotic medication', even if not meeting the criteria for TRS. New findings indicate that patients with TRS have abnormalities in the glutamatergic system, but not in dopaminergic transmission, so there is a significant unmet medical need for treatments with a glutamatergic mechanism of action, efficacious both in TRS patients and in those who are poor responders to the current treatments. About evenamide Evenamide is the first new chemical entity that has demonstrated significant benefits in this difficult-to-treat patient population, as seen in the potentially pivotal Phase III study 008A trial, as an add-on treatment to second generation antipsychotics including clozapine, in 291 poorly responding patients with chronic schizophrenia. The primary endpoint, the Positive and Negative Syndrome Scale (PANSS) 1, and the key secondary endpoint, the Clinical Global Impressions Scale – Severity (CGI-S), were met and showed statistical significance compared to placebo. Importantly, evenamide treatment was associated with statistically significant increases in the proportion of patients who experienced 'clinically meaningful benefit' on the outcome variables. Evenamide was extremely well tolerated, without any of the usual side effects of available antipsychotics. About Newron Pharmaceuticals Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on developing novel therapies for patients with diseases of the central and peripheral nervous system. Headquartered in Bresso, near Milan, Italy, Newron is advancing its lead compound, evenamide, a first-in-class glutamate modulator, which has the potential to be the first add-on therapy for treatment-resistant schizophrenia (TRS) and for poorly responding patients with schizophrenia. Evenamide is currently in Phase III development and clinical trial results to date demonstrate the benefits of this drug candidate in the TRS patient population, with significant improvements across key efficacy measures increasing over time, as well as a favourable safety profile, which is uncommon for available antipsychotic medications. Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea. Newron has a proven track record in bringing CNS therapies to market. Its Parkinson's disease treatment, Xadago® (safinamide), is approved in over 20 markets, including the USA, UK, EU, Switzerland, and Japan, and commercialized in partnerships with Zambon and Meiji Seika. For more information, please visit: Important Notices This document contains forward-looking statements, including (without limitation) about (1) Newron's ability to develop and expand its business, successfully complete development of its current product candidates, the timing of commencement of various clinical trials and receipt of data and current and future collaborations for the development and commercialization of its product candidates, (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron's financial resources, and (4) assumptions underlying any such statements. In some cases, these statements and assumptions can be identified by the fact that they use words such as 'will', 'anticipate', 'estimate', 'expect', 'project', 'intend', 'plan', 'believe', 'target', and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron's strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements. By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation difficulties in enrolling clinical trials, negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions. Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron's research programs, development activities, commercialization plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions. Newron does not undertake any obligation to publicly update or revise forward-looking statements except as may be required by applicable regulations of the SIX Swiss Exchange or the Dusseldorf Stock Exchange where the shares of Newron are listed. This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. 1 Positive and Negative Syndrome Scale (PANSS) is widely used in clinical trials of schizophrenia and is considered the 'gold standard' for assessment of antipsychotic treatment efficacy (Innvo Clin Neurosci, 2017:
